Ulteriori informazioni
Zusatztext Overall, this book provides a good overview of cancer immunotherapy with specific insights into the main clinical treatments and experimental approaches for specialists. Informationen zum Autor Robert C. Rees, Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK Klappentext Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field. Zusammenfassung Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field. Inhaltsverzeichnis 1: Pedro Romero and Pierre G. Coulie: Adaptive T-cell immunity and tumor antigen recognition 2: Gail D. Sckisel, Arta M. Monjazeb, Annie Mirsoian, Anthony E. Zamora, Steven Grossenbacher, and William J. Murphy: Impact of aging and body mass on cancer immunotherapy outcomes 3: Thomas C.C. Tan, Jean-Marc Doisne and Francesco Colucci: The potential of natural killer cells in cancer immunotherapy 4: Russell Hughes and Munitta Muthana: The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy 5: Natalia Aptsiauri, Angel M. Garcia-Lora, Federico Garrido: "Hard" and "soft" loss of MHC class I expression in cancer cells 6: A.G. Dalgleish: Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses 7: Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau, and Suzanne Ostrand-Rosenberg: Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation. 8: Thomas J. Sayers and Neil A Cross: Triggering death receptors as a means of inducing tumoricidal activity 9: Jayakumar Vadakekolathu, Stephanie B. McArdle, David J. Boocock, and Amanda Miles: Identification of tumor antigens for clinical evaluation 10: Peter L. Stern and Kenneth Oguejiofor: Viral antigens as targets for prophylactic and therapeutic intervention in cancer 11: Constantin N. Baxevanis and Sonia A. Perez: HER-2/neu as a target for vaccine and antibody directed therapies 12: Matteo Bellone, Sara Martina Parigi, and Elena Jachetti: Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model 13: Per thor Straten, Dave Schrama, Jürgen C. Becker and Mads Hald Andersen: Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy 14: M. Strioga and E. Tartour: Predictive biomarkers to better select patients for cancer immunotherapy 15: Karishma Rajani, Vanessa Alonso-Camino, Nicolas Boisgerault, Richard Vile: Viral platforms for expression of tumour antigens in cancer immunotherapy 16: Paul Moss: Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies 17: L. G. Durrant, W. Xue, L. R. Machado, R. L. Metheringham, and V. A. Brentville: DNA vaccines 18: Uzoma K. Iheagwaraa, Pamela L. Beattya, Chan Su-Wan Biancaa, Lora H. Rigattid, Ted Ross, and Olivera J. Finn: Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA) 19: Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-Ann Guinn: Vaccination against myeloid leukaemias using newly defined antigens 20: Patrick A. ...
